血管激素转换酶基因的插入-删除变异与各种类型的心力衰竭之间的相关性
Rawaz D Tawfeeq1, Ava T Ismael2, Mohammed H Alwan3
1Department of Clinical Analysis, College of Pharmacy, Hawler Medical University. Erbil, 44001, Iraq. rawaz.tawfeeq@hmu.edu.krd.
Cellular and molecular biology (Noisy-le-Grand, France)
|December 30, 2023
概括
血管激素转化酶 (ACE) I/D基因变体,特别是DD基因型,与严重心力衰竭 (HF) 有关. 这一发现可能有助于对HF患者的风险分层和预后.
科学领域:
- 心血管遗传学 心血管遗传学
- 分子心脏病学分子心脏病学
- 遗传流行病学 遗传流行病学
背景情况:
- 血管激素转化酶 (ACE) 基因插入/删除 (I/D) 多态是心血管疾病的已知因素.
- ACE I/D变化与心力衰竭 (HF) 严重程度之间的关联需要进一步确认.
研究的目的:
- 调查ACE I/D基因变异与心力衰竭 (HF) 严重程度之间的关联.
- 为了确定特定的ACE基因型是否与先进的NYHA类或减少的射出分数相关.
主要方法:
- 使用聚合酶链反应 (PCR) 进行ACE I/D多态的基因定型.
- 分析了所有NYHA类的150名HF患者和90名年龄/性别匹配的健康对照.
- 心声造影以评估HF患者的喷射分数 (EF) 和左心室尺寸.
主要成果:
- 在ACE DD基因型和NYHA类IV心力衰竭之间发现了统计学上显著的关联.
- 对于DD基因型 (与ID和II相比) 的几率比 (OR) 是3.37 (p=0.039).
- 在严重的HF病例中,D等位基因的频率更高 (OR2.55,p=0.049),表明与HF严重程度的联系.
结论:
- ACE基因的DD变异与晚期心力衰竭 (NYHA类IV) 有显著的关联.
- 这种遗传变异可能作为HF严重程度的标志物,影响风险分层和患者预后.
相关概念视频
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
433
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
433
01:22Heart Failure Drugs: Diuretics
388
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
388
01:22Heart Failure Drugs: β-Blockers
341
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
645
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
645
01:26Heart Failure Drugs: Inotropic Agents
591
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
591